Considerations for development of therapies for cutaneous neurofibroma

Sharad Verma, Vincent M. Riccardi, Scott R. Plotkin, Hubert Weinberg, R. Rox Anderson, Jaishri Blakeley, Kurt Jarnagin, James Lee

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: The only therapies currently available for cutaneous neurofibromas (cNF) are procedural. The goals of the Therapies Development Working Group were to (1) summarize currently available treatment options for cNF, (2) define key considerations for drug discovery and development generally, and specifically for cNF, and (3) outline recommendations for the successful development of medical therapies for cNF. METHODS: The subgroup reviewed published and unpublished data on procedural, drug/device, and medical treatment approaches utilized for cNFs via literature search. The team defined disease- and patient-specific factors to consider for therapies development in a series of consensus meetings. RESULTS: The team identified 5 approaches entailing procedural and drug/device methods currently under study. There have been 4 clinical studies exploring various interventional therapies, from which outcomes were highly variable. The team identified 4 key factors to prioritize during the development of products for the treatment for cNF: safety, anatomic distribution of cNF, numbers of tumors to be treated, and route of administration. CONCLUSIONS: The number, size, and distribution of cNF is highly variable among patients with NF1 and it is possible that different phenotypes will require different drug development paths. The nonfatal nature of the disease and relatively limited patient numbers suggest that for any product to have a higher likelihood of acceptance, it will have to (1) demonstrate an effect that is clinically meaningful, (2) have a safety profile conducive to long-term dosing, and (3) have a low manufacturing cost.

Original languageEnglish (US)
Pages (from-to)S21-S30
JournalNeurology
Volume91
Issue number2
DOIs
StatePublished - Jul 10 2018

Fingerprint

Neurofibroma
Skin
Therapeutics
Pharmaceutical Preparations
Safety
Equipment and Supplies
Drug Discovery
Phenotype
Costs and Cost Analysis

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Verma, S., Riccardi, V. M., Plotkin, S. R., Weinberg, H., Anderson, R. R., Blakeley, J., ... Lee, J. (2018). Considerations for development of therapies for cutaneous neurofibroma. Neurology, 91(2), S21-S30. https://doi.org/10.1212/WNL.0000000000005791

Considerations for development of therapies for cutaneous neurofibroma. / Verma, Sharad; Riccardi, Vincent M.; Plotkin, Scott R.; Weinberg, Hubert; Anderson, R. Rox; Blakeley, Jaishri; Jarnagin, Kurt; Lee, James.

In: Neurology, Vol. 91, No. 2, 10.07.2018, p. S21-S30.

Research output: Contribution to journalArticle

Verma, S, Riccardi, VM, Plotkin, SR, Weinberg, H, Anderson, RR, Blakeley, J, Jarnagin, K & Lee, J 2018, 'Considerations for development of therapies for cutaneous neurofibroma', Neurology, vol. 91, no. 2, pp. S21-S30. https://doi.org/10.1212/WNL.0000000000005791
Verma, Sharad ; Riccardi, Vincent M. ; Plotkin, Scott R. ; Weinberg, Hubert ; Anderson, R. Rox ; Blakeley, Jaishri ; Jarnagin, Kurt ; Lee, James. / Considerations for development of therapies for cutaneous neurofibroma. In: Neurology. 2018 ; Vol. 91, No. 2. pp. S21-S30.
@article{4cbd5031d130400ab27bc28bb4d85c9c,
title = "Considerations for development of therapies for cutaneous neurofibroma",
abstract = "OBJECTIVE: The only therapies currently available for cutaneous neurofibromas (cNF) are procedural. The goals of the Therapies Development Working Group were to (1) summarize currently available treatment options for cNF, (2) define key considerations for drug discovery and development generally, and specifically for cNF, and (3) outline recommendations for the successful development of medical therapies for cNF. METHODS: The subgroup reviewed published and unpublished data on procedural, drug/device, and medical treatment approaches utilized for cNFs via literature search. The team defined disease- and patient-specific factors to consider for therapies development in a series of consensus meetings. RESULTS: The team identified 5 approaches entailing procedural and drug/device methods currently under study. There have been 4 clinical studies exploring various interventional therapies, from which outcomes were highly variable. The team identified 4 key factors to prioritize during the development of products for the treatment for cNF: safety, anatomic distribution of cNF, numbers of tumors to be treated, and route of administration. CONCLUSIONS: The number, size, and distribution of cNF is highly variable among patients with NF1 and it is possible that different phenotypes will require different drug development paths. The nonfatal nature of the disease and relatively limited patient numbers suggest that for any product to have a higher likelihood of acceptance, it will have to (1) demonstrate an effect that is clinically meaningful, (2) have a safety profile conducive to long-term dosing, and (3) have a low manufacturing cost.",
author = "Sharad Verma and Riccardi, {Vincent M.} and Plotkin, {Scott R.} and Hubert Weinberg and Anderson, {R. Rox} and Jaishri Blakeley and Kurt Jarnagin and James Lee",
year = "2018",
month = "7",
day = "10",
doi = "10.1212/WNL.0000000000005791",
language = "English (US)",
volume = "91",
pages = "S21--S30",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Considerations for development of therapies for cutaneous neurofibroma

AU - Verma, Sharad

AU - Riccardi, Vincent M.

AU - Plotkin, Scott R.

AU - Weinberg, Hubert

AU - Anderson, R. Rox

AU - Blakeley, Jaishri

AU - Jarnagin, Kurt

AU - Lee, James

PY - 2018/7/10

Y1 - 2018/7/10

N2 - OBJECTIVE: The only therapies currently available for cutaneous neurofibromas (cNF) are procedural. The goals of the Therapies Development Working Group were to (1) summarize currently available treatment options for cNF, (2) define key considerations for drug discovery and development generally, and specifically for cNF, and (3) outline recommendations for the successful development of medical therapies for cNF. METHODS: The subgroup reviewed published and unpublished data on procedural, drug/device, and medical treatment approaches utilized for cNFs via literature search. The team defined disease- and patient-specific factors to consider for therapies development in a series of consensus meetings. RESULTS: The team identified 5 approaches entailing procedural and drug/device methods currently under study. There have been 4 clinical studies exploring various interventional therapies, from which outcomes were highly variable. The team identified 4 key factors to prioritize during the development of products for the treatment for cNF: safety, anatomic distribution of cNF, numbers of tumors to be treated, and route of administration. CONCLUSIONS: The number, size, and distribution of cNF is highly variable among patients with NF1 and it is possible that different phenotypes will require different drug development paths. The nonfatal nature of the disease and relatively limited patient numbers suggest that for any product to have a higher likelihood of acceptance, it will have to (1) demonstrate an effect that is clinically meaningful, (2) have a safety profile conducive to long-term dosing, and (3) have a low manufacturing cost.

AB - OBJECTIVE: The only therapies currently available for cutaneous neurofibromas (cNF) are procedural. The goals of the Therapies Development Working Group were to (1) summarize currently available treatment options for cNF, (2) define key considerations for drug discovery and development generally, and specifically for cNF, and (3) outline recommendations for the successful development of medical therapies for cNF. METHODS: The subgroup reviewed published and unpublished data on procedural, drug/device, and medical treatment approaches utilized for cNFs via literature search. The team defined disease- and patient-specific factors to consider for therapies development in a series of consensus meetings. RESULTS: The team identified 5 approaches entailing procedural and drug/device methods currently under study. There have been 4 clinical studies exploring various interventional therapies, from which outcomes were highly variable. The team identified 4 key factors to prioritize during the development of products for the treatment for cNF: safety, anatomic distribution of cNF, numbers of tumors to be treated, and route of administration. CONCLUSIONS: The number, size, and distribution of cNF is highly variable among patients with NF1 and it is possible that different phenotypes will require different drug development paths. The nonfatal nature of the disease and relatively limited patient numbers suggest that for any product to have a higher likelihood of acceptance, it will have to (1) demonstrate an effect that is clinically meaningful, (2) have a safety profile conducive to long-term dosing, and (3) have a low manufacturing cost.

UR - http://www.scopus.com/inward/record.url?scp=85070660927&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070660927&partnerID=8YFLogxK

U2 - 10.1212/WNL.0000000000005791

DO - 10.1212/WNL.0000000000005791

M3 - Article

C2 - 29987132

AN - SCOPUS:85070660927

VL - 91

SP - S21-S30

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 2

ER -